InvestorsObserver
×
News Home

Is Immix Biopharma Inc (IMMX) a Bad Choice in Biotechnology Wednesday?

Wednesday, November 29, 2023 01:11 PM | InvestorsObserver Analysts

Mentioned in this article

Is Immix Biopharma Inc (IMMX) a Bad Choice in Biotechnology Wednesday?

The 89 rating InvestorsObserver gives to Immix Biopharma Inc (IMMX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 99 percent of stocks in the Biotechnology industry, IMMX’s 89 overall rating means the stock scores better than 89 percent of all stocks.

Overall Score - 89
IMMX has an Overall Score of 89. Find out what this means to you and get the rest of the rankings on IMMX!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 89 would rank higher than 89 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Immix Biopharma Inc Stock Today?

Immix Biopharma Inc (IMMX) stock is lower by -5.68% while the S&P 500 has gained 0.25% as of 1:01 PM on Wednesday, Nov 29. IMMX is down -$0.30 from the previous closing price of $5.28 on volume of 212,387 shares. Over the past year the S&P 500 is higher by 15.38% while IMMX has gained 308.20%. IMMX lost -$0.92 per share the over the last 12 months. Click Here to get the full Stock Report for Immix Biopharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App